trending Market Intelligence /marketintelligence/en/news-insights/trending/gZMo7cT1EY-k-J8XEsG1Lw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US appeals court dismisses Amgen's demand to ban Sanofi, Regeneron drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US appeals court dismisses Amgen's demand to ban Sanofi, Regeneron drug

The U.S. Court of Appeals for the Federal Circuit dismissed a permanent injunction on the sale of Sanofi and Regeneron Pharmaceuticals Inc.'s cholesterol-lowering drug Praluent, Reuters reported Oct. 5.

Amgen Inc., which markets a rival cholesterol drug, Repatha, had brought a lawsuit claiming that Praluent infringed on two of its patents related to a protein known as proprotein convertase subtilisin/kexin 9, or PCSK9.

U.S. District Judge Sue Robinson in Delaware granted Amgen's motion in January, banning Sanofi and Regeneron from selling and making Praluent in the U.S.

However, the U.S. Court of Appeals for the Federal Circuit in February allowed Praluent sales to continue while the firms sorted out the patent infringement suit.